Home/Pipeline/GRC-301

GRC-301

Neuropathic Pain

PreclinicalCandidate optimization

Key Facts

Indication

Neuropathic Pain

Phase

Preclinical

Status

Candidate optimization

Company

Grace Therapeutics

About Grace Therapeutics

Grace Therapeutics is a public, clinical-stage biotech company focused on discovering and developing novel therapeutics for rare neurological and neurodevelopmental disorders. Its core strategy is built on a proprietary platform targeting specific neuronal ion channels to address hyperexcitability disorders, with lead programs in rare focal epilepsies and treatment-resistant seizures. The company is actively enrolling patients in Phase 2 and Phase 1/2 trials, positioning itself in a high-need, growing segment of the neurology market. Founded in 2019, Grace seeks to build a sustainable R&D engine to advance its pipeline and address significant unmet medical needs.

View full company profile

Therapeutic Areas

Neurology Neurodevelopmental Disorders

Other Neuropathic Pain Drugs

Drug	Company	Phase	Status
Peripheral nerve pain agent	Nyrada	Preclinical	Active
NTRX-07	NeuroTherapia	Pre-clinical	Active
Neuropathic Pain Model Service	NeuroProof	Pre-clinical	Active
Sana Device for Neuropathic Pain	Sana Health	Pivotal Trial Completed	Active
Neuropathic Pain Program	VersaPeutics	Preclinical	Active
Cerebro Platform for Pain	Vonova.io	Pre-clinical	Active
LAT9997	Lateral Pharma	Phase 2 (next-gen)	Active; composition-of-matter patent secured
ZYNPN	Zyneyro	Pre-clinical	Active
XT-150 (Preclinical)	Xalud Therapeutics	Preclinical	Active
ONO-2910	Ono Pharmaceutical	Phase 2	Active
VX-548	Vertex Pharmaceuticals	Phase 2	Active
BDT272	KYORIN Pharmaceutical	Preclinical	Active (In-licensed)